Journal
EXPERT REVIEW OF NEUROTHERAPEUTICS
Volume 10, Issue 5, Pages 711-728Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1586/ERN.10.29
Keywords
amyloid-beta; beta-secretase; gamma-secretase; Alzheimer's disease; dementia; immunotherapy; tau; therapeutic; treatment
Categories
Funding
- Elan
- Janssen
- Bristol-Myers Squibb
- Medivation
- Pfizer
- Alzheimer's Disease Cooperative Study (ADCS)
- NATIONAL INSTITUTE ON AGING [P50AG016570] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Alzheimer's disease is a progressive neurodegenerative disease for which no cure exists. There is a substantial need for new therapies that offer improved symptomatic benefit and disease-slowing capabilities. In recent decades there has been substantial progress in understanding the molecular and cellular changes associated with Alzheimer's disease pathology. This has resulted in identification of a large number of new drug targets. These targets include, but are not limited to, therapies that aim to prevent production of or remove the amyloid-beta protein that accumulates in neuritic plaques; to prevent the hyperphosphorylation and aggregation into paired helical filaments of the microtubule-associated protein tau; and to keep neurons alive and functioning normally in the face of these pathologic challenges. We provide a review of these targets for drug development.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available